Paul-Langerhans-Institut Dresden of the German Center for Diabetes Research (DZD e.V.)

What Paul-Langerhans-Institut Dresden of the German Center for Diabetes Research (DZD e.V.) does

Paul-Langerhans-Institut Dresden (PLID) is a non-profit academic research institute headquartered in Dresden, Germany, dedicated to investigating the causal cellular and molecular mechanisms underlying the impairment and loss of pancreatic islet beta cells — the root origin of all forms of diabetes mellitus. The institute conducts basic research, translational research, epidemiology, and clinical studies focused on understanding how the body processes sugar, the role of insulin, and the involvement of other organs (muscles, brain) in glucose metabolism, with the stated aim of contributing to new therapeutic options, prevention, and treatment measures for diabetes.

PLID was established as a founding partner of the German Center for Diabetes Research (DZD e.V.) in 2009 and has operated as a satellite institute of Helmholtz Zentrum München (Helmholtz Munich) since January 2015. It is hosted within the Medical Faculty of TU Dresden and the University Hospital Carl Gustav Carus, with additional collaboration links to the Center for Regenerative Therapies Dresden (CRTD). The institute's primary "products" are scientific publications — 96 peer-reviewed articles were published in 2018 alone in journals including the New England Journal of Medicine, Nature Immunology, Nature Reviews Endocrinology, PNAS, JAMA, and the Journal of Cell Biology — and clinical translation of research findings into prevention and treatment practice via the DZD network.

The institute operates as a publicly funded entity with no commercial revenue model. Funding flows from the German federal government through DZD, from Helmholtz Munich as parent/satellite relationship, from TU Dresden and the Medical Faculty, and from the Free State of Saxony via a co-financed budget approved by the Landtag. With a reported headcount of around 10 employees, PLID functions as a focused research unit rather than a large standalone organization, leveraging institutional partnerships to access clinical populations, large-scale study infrastructure, and interdisciplinary expertise.

Name

Paul-Langerhans-Institut Dresden of the German Center for Diabetes Research (DZD e.V.)

Legal name

Paul Langerhans Institute Dresden

Website

https://plid.de

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Paul-Langerhans-Institut Dresden (PLID) is a publicly funded non-profit research institute in Dresden, Germany, studying the cellular and molecular mechanisms of pancreatic islet beta cell loss in diabetes mellitus. It operates as a satellite of Helmholtz Munich and founding partner of the DZD, serving the academic and clinical diabetes research community.

Ownership category

akta.pro rank

Product category

Diabetes Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

akta.pro primary industry

Diabetes (General) (HLAKADAA)

Keywords

• Diabetes research
• Pancreatic beta cells
• Translational medicine
• Clinical endocrinology
• Metabolic disease research

Headquarters

HQ city

Dresden

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Funding: The institute operates as a publicly funded research institution receiving support from the German government through the DZD (German Center for Diabetes Research) founded in 2009, Helmholtz Munich as a satellite institute since January 2015, and TU Dresden/Medical Faculty. Funding is supplemented by tax funds from the Free State of Saxony co-financed budget approved by the Landtag.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

The Paul Langerhans Institute Dresden (PLID) conducts basic, translational, epidemiological, and clinical research focused on diabetes mellitus, with a central focus on deciphering the causal mechanisms behind the impairment and loss of pancreatic islet beta cells. The institute operates within the German Center for Diabetes Research (DZD) network to enable large-scale, interdisciplinary research and accelerate translation of findings into prevention measures and clinical treatments.

Product overview

Paul Langerhans Institute Dresden (PLID) is a research institute focused on diabetes research, specifically studying the causal mechanisms of pancreatic islet beta cell impairment and loss that lead to diabetes. The institute is a founding partner of the German Center for Diabetes Research (DZD e.V.) and a satellite institute of Helmholtz Munich since January 2015. The institute conducts basic research, translational research, epidemiology, and clinical application studies through the DZD network. It does not offer commercial products or services; rather, it produces scientific publications and conducts academic research.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• Helmholtz Zentrum München (Helmholtz Munich)coreStrategic or Co-development Partner · 1 January 2015PLID has been a satellite institute of Helmholtz Munich since January 2015. The institute is also known as the Paul Langerhans Institute of the Helmholtz Zentrum München at the University Hospital Carl Gustav Carus and the Medical Faculty of TU Dresden.
• German Center for Diabetes Research (DZD e.V.)coreStrategic or Co-development Partner · 1 January 2009PLID is a founding-partner of the DZD, a national research association created by the German government in 2009. DZD brings together experts in diabetes research enabling close interaction between basic research, epidemiology, translational research, and clinical application for successful research and effective prevention/treatment measures.
• University Hospital Carl Gustav Carus DresdencoreStrategic or Co-development PartnerThe institute is associated with University Hospital Carl Gustav Carus, one of the leading university hospitals in Germany, enabling clinical research translation and access to patient populations for studies.
• TU Dresden / Medical Faculty of TU DresdencoreStrategic or Co-development PartnerThe institute is hosted by the Medical Faculty of TU Dresden, contributing to the academic ecosystem and enabling collaboration with the broader university research community.
• Center for Regenerative Therapies Dresden (CRTD)minorStrategic or Co-development PartnerCRTD is listed as a partner organization, indicating collaboration in regenerative medicine research areas potentially related to diabetes treatment approaches.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• German Diabetes Center (DDZ) Düsseldorf: DDZ is another founding-partner of the German Center for Diabetes Research (DZD) and focuses on diabetes research and treatment, making it PLID's most direct domestic peer with shared funding sources, network affiliation, and scientific mission.
• Joslin Diabetes Center: Joslin is the world's largest diabetes research center and clinical care provider, affiliated with Harvard Medical School. It shares PLID's focus on pancreatic islet biology and diabetes pathophysiology but operates at substantially greater scale and with direct clinical care delivery.
• Institute for Diabetes Research (IDF) at Helmholtz Munich: IDF is the dedicated diabetes research arm of Helmholtz Munich and operates under the same parent as PLID. It conducts basic and clinical diabetes research with comparable scientific goals, including beta cell biology, making it a closely aligned peer within the Helmholtz ecosystem.
• Vanderbilt Diabetes Research and Training Center: A major US-based academic diabetes research center affiliated with Vanderbilt University Medical Center. It conducts basic, translational, and clinical diabetes research with comparable scientific mission, particularly in islet biology and metabolic disease mechanisms.
• Steno Diabetes Center: Steno is a leading European diabetes research and clinical care center based in Denmark, with a similar mission of integrating research, prevention, and treatment. It serves as a relevant international peer given its comparable focus on translational diabetes science.

Broad incumbents

• Helmholtz Munich (Helmholtz Zentrum München): Helmholtz Munich is PLID's parent organization since 2015 and operates one of Europe's largest biomedical research centers with a dedicated Institute for Diabetes Research. It is the broader institutional incumbent providing PLID with satellite affiliation and shared research infrastructure.
• Max Planck Institute for Metabolism Research: Located in Cologne, this Max Planck institute investigates metabolism and metabolic disease including diabetes. It shares PLID's basic research orientation and German public-funding model but operates with broader scope and substantially larger headcount.

Regional players

• Center for Regenerative Therapies Dresden (CRTD): CRTD is PLID's local partner in Dresden, focused on regenerative biology and cell-based therapies. The overlap with PLID's beta cell research creates an emerging peer/dynamic in regenerative approaches to diabetes, though CRTD covers a broader disease scope.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/PLID_Info
• LinkedInlinkedin.com/company/paul-langerhans-institut-dresden

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paul-Langerhans-Institut Dresden of the German Center for Diabetes Research (DZD e.V.)